Deal Watch: AstraZeneca Buys, Sells And Partners In Busy Week
Executive Summary
In frenetic week, AstraZeneca signs PD-L1 combo study pact, buys data-analysis firm and divests generalized lipodystrophy drug to Aegerion to focus pipeline efforts on core areas. Merck becomes the latest big pharma to sign on with Bind, and Astellas and Proteostasis agree to an R&D collaboration in unfolded protein response.